HHCP
IONS icon

Hilton Head Capital Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Hilton Head Capital Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.36K Sell
55
-298
-84% -$22.4K ﹤0.01% 690
2026
Q1 		$26.5K Sell
353
-246
-41% -$19.4K 0.01% 412
2025
Q4 		$47.4K Buy
+599
New +$45.1K 0.03% 298

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Hilton Head Capital Partners's IONS Position: Q2 2026 in Review

Hilton Head Capital Partners reduced its Ionis Pharmaceuticals (IONS) stake by 84% in Q2 2026, selling an estimated $22.4K and leaving 55 shares worth $4.36K. The position accounts for ﹤0.01% of the portfolio, ranked #690.

Hilton Head Capital Partners first reported a position in IONS in Q4 2025 and has held it in 3 quarters since. The position peaked at $47.4K in Q4 2025. 511 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Hilton Head Capital Partners held 55 shares of Ionis Pharmaceuticals worth $4.36K as of Q2 2026.
  • Hilton Head Capital Partners sold 298 Ionis Pharmaceuticals shares in Q2 2026, an estimated $22.4K.
  • Ionis Pharmaceuticals made up ﹤0.01% of Hilton Head Capital Partners's portfolio in Q2 2026, its #690 holding.
  • Hilton Head Capital Partners first reported a position in Ionis Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Hilton Head Capital Partners's Ionis Pharmaceuticals position peaked at $47.4K in Q4 2025.
  • 511 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Hilton Head Capital Partners's 13F filing for Q2 2026, filed 27 Jul 2026.